AR039698A1 - Agonistas de los receptores cannabinoides - Google Patents
Agonistas de los receptores cannabinoidesInfo
- Publication number
- AR039698A1 AR039698A1 ARP030102152A ARP030102152A AR039698A1 AR 039698 A1 AR039698 A1 AR 039698A1 AR P030102152 A ARP030102152 A AR P030102152A AR P030102152 A ARP030102152 A AR P030102152A AR 039698 A1 AR039698 A1 AR 039698A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- unsubstituted
- group
- heteroaryl
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
- C07D213/643—2-Phenoxypyridines; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/64—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Abstract
Compuestos antagonistas de receptores cannabinoides, sus composiciones farmacéuticas, métodos para preparar dichas composiciones farmacéuticas y métodos de uso de las mismas. Reivindicación 1: Un compuesto representado por la fórmula estructural (1) o su sal o solvato farmacéuticamente aceptable; en la cual: R1 se selecciona entre el grupo que consiste en hidrógeno, alquilo sustituido o insustituido, alquenilo sustituido o insustituido, haloalquilo, -N(R7)2, cicloalquilo sustituido o insustituido, cicloheteroalquilo sustituido o insustituido, arilo sustituido o insustituido, y heteroarilo sustituido o insustituido, en donde el término "sustituido" significa estando sustituido con (X)p; R2 se selecciona entre el grupo que consiste en hidrógeno, alquilo sustituido o insustituido, alquenilo sustituido o insustituido, haloalquilo, -N(R7)2, cicloalquilo sustituido o insustituido, cicloheteroalquilo sustituido o insustituido, arilo sustituido o insustituido, y heteroarilo sustituido o insustituido, en donde el término "sustituido" significa estando sustituido con (X)p; R3 se selecciona entre el grupo que consiste en alquilo, heteroalquilo, arilo, heteroarilo, Br, Cl, F, CF3, OCF2H, OCF3 y alcoxi, en donde R3 puede ser igual o diferente y se selecciona independientemente cuando n > 1; R4 se selecciona entre el grupo que consiste en H, alquilo sustituido o insustituido, alquenilo sustituido o insustituido, cicloalquilo sustituido o insustituido, cicloheteroalquilo sustituido o insustituido, arilo sustituido o insustituido, y heteroarilo sustituido o insustituido, en donde el término "sustituido" significa estando sustituido con (X)p; R5 y R6, los cuales pueden ser iguales o diferentes, se seleccionan independientemente entre el grupo que consiste en H, alquilo sustituido o insustituido, alquenilo sustituido o insustituido, cicloalquilo sustituido o insustituido, cicloheteroalquilo sustituido o insustituido, arilo sustituido o insustituido, y heteroarilo sustituido o insustituido, en donde el término "sustituido" significa estando sustituido con (X)p; R7 se selecciona entre el grupo que consiste en hidrógeno, alquilo sustituido o insustituido, alquenilo sustituido o insustituido, haloalquilo, cicloalquilo sustituido o insustituido, cicloheteroalquilo, arilo sustituido o insustituido, y heteroarilo sustituido o insustituido, o dos grupos R7 pueden formar un anillo de 4-7 átomos de carbono, en donde el término "sustituido" significa estando sustituido con (X)p; L1 se selecciona entre el grupo que consiste en -C(R2)2, -C(O)-, -(CH(OR2))-, -S(O2), -S(O)-, -S-, -O-, -N(R2)-, -C(O)N(H)-, -N(H)C(O)-, CF2-, -CH=N-O-R2 y -CH(NHOR2)-; L2 se selecciona entre el grupo que consiste en un enlace covalente, -CH2-, -CH(CH3)-, -C(CH3)2-, -CH=N-O-R2, -S(O2)-, -S(O), -S-, -C(O)-, -O-, -N(R2)-, -C(O)N(H)- y -N(H)C(O)-; M es una porción heteroarilo; n es 0-4; p es 0-5; X puede ser igual o diferente y se selecciona entre el grupo que consiste en Br, Cl, F, CF3, OH, OCF2H, OCF3, alcoxi, alquilo, cicloalquilo, -O-cicloalquilo, heteroalquilo, -C(O)N(R7)2, -S(O2)R2 y -OS(O2)R2, en donde X se selecciona independientemente cuando p > 1; Y se selecciona entre el grupo que consiste en un enlace covalente, -CH2-, -S(O2)- y -C(O)-; y Z se selecciona entre el grupo que consiste en un enlace covalente, -CH2-, -S(O2)- y -C(O)-, con las siguientes condiciones: cuando L2 es un enlace covalente, M está directamente ligado a R4; cuando Y es un enlace covalente, R1 está directamente ligado al átomo de nitrógeno mostrando en la fórmula (1); y cuando Z es un enlace covalente, R2 está directamente ligado al átomo de nitrógeno mostrando en la fórmula (1).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38978802P | 2002-06-19 | 2002-06-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR039698A1 true AR039698A1 (es) | 2005-03-09 |
Family
ID=30000466
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP030102152A AR039698A1 (es) | 2002-06-19 | 2003-06-18 | Agonistas de los receptores cannabinoides |
Country Status (14)
Country | Link |
---|---|
US (1) | US7217732B2 (es) |
EP (1) | EP1539693B9 (es) |
JP (1) | JP2005533809A (es) |
CN (1) | CN1662496A (es) |
AR (1) | AR039698A1 (es) |
AT (1) | ATE388937T1 (es) |
AU (1) | AU2003243637A1 (es) |
CA (1) | CA2487346A1 (es) |
DE (1) | DE60319714T2 (es) |
ES (1) | ES2303599T3 (es) |
MX (1) | MXPA04012704A (es) |
PE (1) | PE20040574A1 (es) |
TW (1) | TW200405892A (es) |
WO (1) | WO2004000807A1 (es) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7067539B2 (en) * | 2001-02-08 | 2006-06-27 | Schering Corporation | Cannabinoid receptor ligands |
US6897220B2 (en) * | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
US7868204B2 (en) * | 2001-09-14 | 2011-01-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
BR0212510A (pt) * | 2001-09-14 | 2004-08-24 | Methylgene Inc | Inibidor de histona desacetilase, composto e composição |
UY27939A1 (es) | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | Compuestos |
ATE496901T1 (de) * | 2003-05-20 | 2011-02-15 | Univ Tennessee Res Foundation | Cannabinoidderivate, verfahren zu deren herstellung und deren verwendung |
EP1661572A1 (en) * | 2003-08-18 | 2006-05-31 | Shionogi & Co., Ltd. | Novel use of cannabinoid receptor agonist |
ES2308226T3 (es) * | 2003-09-11 | 2008-12-01 | Sandoz Ag | Proceso para la produccion de micofenolato mofetil. |
WO2005030705A1 (en) * | 2003-09-24 | 2005-04-07 | Methylgene, Inc. | Inhibitors of histone deacetylase |
EP1701940B1 (en) * | 2003-12-23 | 2008-05-28 | H.Lundbeck A/S | 2-(1h-indolylsulfanyl)-benzyl amine derivatives as ssri |
GB0402355D0 (en) * | 2004-02-03 | 2004-03-10 | Glaxo Group Ltd | Novel compounds |
US7253204B2 (en) * | 2004-03-26 | 2007-08-07 | Methylgene Inc. | Inhibitors of histone deacetylase |
CA2567602A1 (en) * | 2004-05-21 | 2006-01-05 | The Uab Research Foundation | Compositions and methods relating to pyrimidine synthesis inhibitors |
AR052308A1 (es) * | 2004-07-16 | 2007-03-14 | Lundbeck & Co As H | Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto |
US7629473B2 (en) * | 2005-06-17 | 2009-12-08 | H. Lundbeck A/S | 2-(1H-indolylsulfanyl)-aryl amine derivatives |
AR054393A1 (es) * | 2005-06-17 | 2007-06-20 | Lundbeck & Co As H | Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos. |
JP2009526070A (ja) * | 2006-02-09 | 2009-07-16 | シェーリング コーポレイション | Hcvプロテアーゼ阻害薬とhcvポリメラーゼ阻害薬との組み合わせ、ならびにそれらに関連する処置の方法 |
KR101495611B1 (ko) * | 2006-04-07 | 2015-02-25 | 메틸진 인코포레이티드 | 히스톤 데아세틸라아제의 억제제 |
EP2081905B1 (en) * | 2006-07-28 | 2012-09-12 | Boehringer Ingelheim International GmbH | Sulfonyl compounds which modulate the cb2 receptor |
CN101516839A (zh) | 2006-09-25 | 2009-08-26 | 贝林格尔.英格海姆国际有限公司 | 调节cb2受体的化合物 |
US8940900B2 (en) | 2007-02-28 | 2015-01-27 | Advinus Therapeutics Private Limited | 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application |
JP5492092B2 (ja) | 2007-11-07 | 2014-05-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体を調節する化合物 |
JP5749162B2 (ja) | 2008-07-10 | 2015-07-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体を調節するスルホン化合物 |
BRPI0919172A2 (pt) | 2008-09-25 | 2015-12-15 | Boehringer Ingelheim Int | compostos os quais modulam seletivamente o receptor de cb2 |
US8299103B2 (en) | 2009-06-15 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
WO2011037795A1 (en) | 2009-09-22 | 2011-03-31 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the cb2 receptor |
WO2011088015A1 (en) | 2010-01-15 | 2011-07-21 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
JP5855095B2 (ja) | 2010-06-07 | 2016-02-09 | ノボメディックス,エルエルシーNovomedix,Llc | フラニル化合物およびその使用 |
EP2595959B1 (en) | 2010-07-22 | 2015-11-04 | Boehringer Ingelheim International GmbH | Sulfonyl compounds which modulate the cb2 receptor |
EP2803668A1 (en) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
US9636298B2 (en) | 2014-01-17 | 2017-05-02 | Methylgene Inc. | Prodrugs of compounds that enhance antifungal activity and compositions of said prodrugs |
CN112552200B (zh) * | 2019-09-10 | 2024-03-12 | 烟台药物研究所 | 一种光学纯4-(1-氨基)乙基苯甲酸酯及其盐的制备方法 |
CN111909053B (zh) * | 2020-08-06 | 2022-12-06 | 湖北省生物农药工程研究中心 | 基于二芳胺单元的酰胺类衍生物及其制备方法和应用 |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2419199A (en) * | 1945-02-09 | 1947-04-22 | Parke Davis & Co | Quinoline compounds and process of making same |
JPS5630893A (en) * | 1979-08-24 | 1981-03-28 | Sumitomo Chem Co Ltd | Recording paper |
US4466965A (en) | 1982-07-26 | 1984-08-21 | American Hospital Supply Corporation | Phthalazine compounds, compositions and use |
US4567184A (en) | 1982-12-01 | 1986-01-28 | Usv Pharmaceutical Corporation | Certain aryl or hetero-aryl derivatives of 1-hydroxy-pentane or 1-hydroxy-hexane which are useful for treating inflammation and allergies |
NZ213986A (en) | 1984-10-30 | 1989-07-27 | Usv Pharma Corp | Heterocyclic or aromatic compounds, and pharmaceutical compositions containing such |
JPH0647578B2 (ja) * | 1986-10-08 | 1994-06-22 | 宇部興産株式会社 | アラルキルアミノピリミジン誘導体、その製造法並びに該誘導体を有効成分とする殺虫剤、殺ダニ剤及び殺菌剤 |
JPH0625159B2 (ja) * | 1987-09-10 | 1994-04-06 | 宇部興産株式会社 | アラルキルアミノピリミジン誘導体、その製造法並びに該誘導体を有効成分とする殺虫剤、殺ダニ剤及び殺菌剤 |
DE3766475D1 (de) | 1986-11-03 | 1991-01-10 | Merck & Co Inc | 4-(benzoyl)thiophen(oder furan)-sulfonamid und derivate fuer die aeusserliche behandlung von erhoehtem augeninnendruck. |
JP2531989B2 (ja) * | 1988-09-14 | 1996-09-04 | 吉富製薬株式会社 | ピリジン化合物 |
JP2861104B2 (ja) * | 1988-10-14 | 1999-02-24 | 三菱化学株式会社 | ピラゾールアミド類およびこれを有効成分とする殺虫、殺ダニ剤 |
US5064825A (en) | 1989-06-01 | 1991-11-12 | Merck & Co., Inc. | Angiotensin ii antagonists |
KR920701167A (ko) | 1989-07-07 | 1992-08-11 | 에릭 에스. 딕커 | 약제학적 활성 화합물 |
US5332820A (en) | 1991-05-20 | 1994-07-26 | E. I. Du Pont De Nemours And Company | Dibenzobicyclo(2.2.2) octane angiotensin II antagonists |
US5506227A (en) | 1992-04-13 | 1996-04-09 | Merck Frosst Canada, Inc. | Pyridine-substituted benzyl alcohols as leukotriene antagonists |
JPH0672979A (ja) | 1992-06-08 | 1994-03-15 | Hiroyoshi Hidaka | アミノベンジル誘導体 |
US5338753A (en) | 1992-07-14 | 1994-08-16 | Sumner H. Burstein | (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics |
WO1994005642A1 (en) * | 1992-08-28 | 1994-03-17 | Ciba-Geigy Ag | Indazole derivatives |
US5486525A (en) | 1993-12-16 | 1996-01-23 | Abbott Laboratories | Platelet activating factor antagonists: imidazopyridine indoles |
FR2714057B1 (fr) | 1993-12-17 | 1996-03-08 | Sanofi Elf | Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant. |
EP1195372A1 (en) | 1994-04-18 | 2002-04-10 | Mitsubishi Pharma Corporation | N-heterocyclic substituted benzamide derivatives with antihypertensive activity |
US5596106A (en) | 1994-07-15 | 1997-01-21 | Eli Lilly And Company | Cannabinoid receptor antagonists |
IT1271266B (it) | 1994-12-14 | 1997-05-27 | Valle Francesco Della | Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi |
JPH10513442A (ja) | 1995-02-02 | 1998-12-22 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 5−htレセプターアンタゴニストとしてのインドール誘導体 |
US5532237A (en) | 1995-02-15 | 1996-07-02 | Merck Frosst Canada, Inc. | Indole derivatives with affinity for the cannabinoid receptor |
GB9508748D0 (en) * | 1995-04-28 | 1995-06-14 | British Biotech Pharm | Benzimidazole derivatives |
FR2735774B1 (fr) | 1995-06-21 | 1997-09-12 | Sanofi Sa | Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant |
DK0848703T3 (da) | 1995-07-21 | 2001-01-02 | Nycomed Austria Gmbh | Derivater af benzosulfonamider som inhibitorer for enzymet cyclooxygenase II |
DE19533644A1 (de) | 1995-09-12 | 1997-03-13 | Nycomed Arzneimittel Gmbh | Neue Benzolsulfonamide |
FR2742148B1 (fr) | 1995-12-08 | 1999-10-22 | Sanofi Sa | Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant |
WO1997029079A1 (fr) | 1996-02-06 | 1997-08-14 | Japan Tobacco Inc. | Composes chimiques et utilisation pharmaceutique |
WO1998010763A1 (en) | 1996-09-13 | 1998-03-19 | Merck & Co., Inc. | Thrombin inhibitors |
US6100259A (en) | 1997-01-21 | 2000-08-08 | Smithkline Beecham Corporation | Cannabinoid receptor modulators |
ATA16597A (de) | 1997-02-03 | 1998-04-15 | Nycomed Austria Gmbh | Neue substituierte p-sulfonylaminobenzol- sulfonsäureamide |
WO1998041519A1 (en) | 1997-03-18 | 1998-09-24 | Smithkline Beecham Corporation | Novel cannabinoid receptor agonists |
DE19718181A1 (de) * | 1997-04-30 | 1998-11-05 | Boehringer Ingelheim Pharma | Disubstituierte bicyclische Heterocyclen, ihre Herstellung und ihre Verwendung als Arzneimittel |
ATE499365T1 (de) | 1997-10-24 | 2011-03-15 | Nissan Chemical Ind Ltd | Sulfamoyl-verbindungen und bakterizide für landwirtschaft oder gartenbau |
WO1999026612A1 (en) | 1997-11-21 | 1999-06-03 | Smithkline Beecham Corporation | Novel cannabinoid receptor modulators |
MY153569A (en) | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
AU1918299A (en) * | 1998-02-23 | 1999-09-06 | Warner-Lambert Company | Substituted quinoxaline derivatives as interleukin-8 receptor antagonists |
HUP0103460A3 (en) | 1998-03-26 | 2002-11-28 | Shionogi & Co | Indole derivatives with antiviral activity and pharmaceutical compositions containing them |
KR20010074779A (ko) | 1998-07-28 | 2001-08-09 | 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 | 치환된 아닐리드 화합물 및 제조방법 |
ATE289593T1 (de) * | 1999-05-06 | 2005-03-15 | Neurogen Corp | Substituierte 4-oxo-chinolin-3-carboxamide als gaba gehirnrezeptorliganden |
MXPA02004985A (es) | 1999-11-26 | 2003-10-14 | Shionogi & Co | Antagonistas del neuropeptido y, y5. |
EP1242366A1 (en) | 1999-12-15 | 2002-09-25 | Axys Pharmaceuticals, Inc. | Salicylamides as serine protease and factor xa inhibitors |
DE60030764T2 (de) | 1999-12-15 | 2007-09-13 | Bristol-Myers Squibb Co. | Biphenyl - sulfonamide als duale angiotensin - endothelin - rezeptor - antagonisten |
EP1259485B1 (en) | 2000-02-29 | 2005-11-30 | Millennium Pharmaceuticals, Inc. | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa |
AU4398801A (en) | 2000-03-22 | 2001-10-03 | Banyu Pharmaceutical Co., Ltd. | Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors |
WO2001074762A2 (en) | 2000-04-03 | 2001-10-11 | Phycogen, Inc. | Arylsulfates and their use as enhancers or inhibitors of bioadhesion to surfaces |
CN1657523A (zh) | 2000-04-28 | 2005-08-24 | 田边制药株式会社 | 环状化合物 |
EP1283039A4 (en) | 2000-05-19 | 2007-05-30 | Takeda Pharmaceutical | INHIBITORS OF -SECRETASE |
US7067539B2 (en) * | 2001-02-08 | 2006-06-27 | Schering Corporation | Cannabinoid receptor ligands |
US7507767B2 (en) * | 2001-02-08 | 2009-03-24 | Schering Corporation | Cannabinoid receptor ligands |
EP1387831A1 (de) * | 2001-05-09 | 2004-02-11 | Bayer CropScience AG | Substituierte arylketone |
AR037352A1 (es) | 2001-11-14 | 2004-11-03 | Schering Corp | Compuestos ligandos de los receptores de los cannabinoides, una composicion farmaceutica , y el uso de dichos compuestos para la manufactura de medicamentos |
GB2384313A (en) * | 2002-01-18 | 2003-07-23 | Qinetiq Ltd | An attitude sensor |
AR040126A1 (es) * | 2002-05-29 | 2005-03-16 | Glaxo Group Ltd | Compuesto de fenilsulfonilo, composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento |
-
2003
- 2003-06-17 EP EP03761108A patent/EP1539693B9/en not_active Expired - Lifetime
- 2003-06-17 ES ES03761108T patent/ES2303599T3/es not_active Expired - Lifetime
- 2003-06-17 WO PCT/US2003/019245 patent/WO2004000807A1/en active Application Filing
- 2003-06-17 CN CN038144417A patent/CN1662496A/zh active Pending
- 2003-06-17 AT AT03761108T patent/ATE388937T1/de not_active IP Right Cessation
- 2003-06-17 MX MXPA04012704A patent/MXPA04012704A/es unknown
- 2003-06-17 AU AU2003243637A patent/AU2003243637A1/en not_active Abandoned
- 2003-06-17 DE DE60319714T patent/DE60319714T2/de not_active Expired - Lifetime
- 2003-06-17 CA CA002487346A patent/CA2487346A1/en not_active Abandoned
- 2003-06-17 JP JP2004515897A patent/JP2005533809A/ja active Pending
- 2003-06-17 US US10/464,174 patent/US7217732B2/en not_active Expired - Fee Related
- 2003-06-17 PE PE2003000610A patent/PE20040574A1/es not_active Application Discontinuation
- 2003-06-18 TW TW092116534A patent/TW200405892A/zh unknown
- 2003-06-18 AR ARP030102152A patent/AR039698A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2004000807A1 (en) | 2003-12-31 |
ATE388937T1 (de) | 2008-03-15 |
CA2487346A1 (en) | 2003-12-31 |
ES2303599T3 (es) | 2008-08-16 |
AU2003243637A1 (en) | 2004-01-06 |
EP1539693B9 (en) | 2008-10-08 |
US7217732B2 (en) | 2007-05-15 |
MXPA04012704A (es) | 2005-03-23 |
DE60319714D1 (de) | 2008-04-24 |
PE20040574A1 (es) | 2004-09-08 |
US20040044051A1 (en) | 2004-03-04 |
JP2005533809A (ja) | 2005-11-10 |
TW200405892A (en) | 2004-04-16 |
EP1539693B1 (en) | 2008-03-12 |
EP1539693A1 (en) | 2005-06-15 |
DE60319714T2 (de) | 2009-04-02 |
CN1662496A (zh) | 2005-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR039698A1 (es) | Agonistas de los receptores cannabinoides | |
PE20020476A1 (es) | Derivados de glucopiranosiloxibencilbenceno y composiciones farmaceuticas que comprenden los mismos | |
CO5601011A2 (es) | Derivados de 3-ciclil-5-(anillo de 5 miembros que contiene nitrogeno) metil-oxazolidinona y su uso como agentes antibacterianos | |
AR063022A1 (es) | Derivados de indol antagonistas del receptor de glucagon, composiciones farmaceuticas que los contienen y usos para tratar diabetes mellitus tipo 2 y estados patologicos relacionados. | |
CO5690608A2 (es) | 4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogena cronica | |
CR10145A (es) | Derivados de tropano útiles en terapia (divisional exp. 6800) | |
CO5721006A2 (es) | Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa | |
WO2009057769A1 (ja) | 新規スルホン酸塩及びその誘導体、光酸発生剤並びにこれを用いたレジスト材料及びパターン形成方法 | |
HRP20090162T1 (en) | Quinolinone-carboxamide compounds as 5-ht4 receptor agonists | |
CU23873B1 (es) | Nuevo procedimiento para la preparación de un intermediario útil en la preparación de imidazotriazinonas sustituidas con sulfonamida | |
CO5700768A2 (es) | Derivados de benzoxazina y sus usos | |
AR009413A1 (es) | Un compuesto, el cual es un derivado de distamicina benzoheterociclico, su utilizacion, un procedimiento para producirlo y una composicionfarmaceutica que lo comprende | |
ECSP077402A (es) | Derivados de 2-amido-4-feniltiazol, su preparación y su aplicación en terapéutica | |
PE20040907A1 (es) | Derivados de anilinopirazol | |
KR880006247A (ko) | 티에노피리디논 및 이의 제조방법 | |
KR870008906A (ko) | 마크로라이드 유도체의 제조방법 | |
JP2010527915A5 (es) | ||
AR042002A1 (es) | Benzoxazinonas sustituidas, proceso de obtencion y usos para tratamiento de enfermedades del sistema nervioso central. | |
DE60010596D1 (de) | Pyridinderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen | |
DE602004020730D1 (de) | Pharmazeutisches verfahren und damit hergestellte verbindungen | |
AR053835A1 (es) | Tetrahidropiridoazepin - 8 - onas como moduladores del receptor de dopamina d2 y compuestos relacionados para el tratamiento de la esquizofrenia y otros trastornos del snc, composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos. | |
TW200613334A (en) | (Methyl)acrylate, polymer and resist compound | |
EA200600487A1 (ru) | Соединения инданилпиперазина, способ их получения и содержащие их фармацевтические композиции | |
AR007108A1 (es) | Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes. | |
KR960007592A (ko) | 신규한 피롤로카바졸 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |